AIDS: Re-emergence of HIV after stopping therapy

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Nature

• Publication date

  1999-10-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/44755PMID 10553903
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

  1999cited by this paper
• Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy

  1999cited by this paper
• Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

  1999cited by this paper
• HIV/AIDS in 1998--gaining the upper hand?

  1998cited by this paper
• Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.

  1998cited by this paper
• A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

  1997cited by this paper
• Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

  1997cited by this paper
• Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.

  1997cited by this paper
• Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

  1997cited by this paper

• Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound.

  2026cites this paper
• Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy

  2026cites this paper
• HIV-specific CD8+ T-cell proliferative response 24 weeks after early antiretroviral therapy initiation is associated with the subsequent reduction in the viral reservoir

  2026cites this paper
• Methaneseleninic acid, a circadian-modulating agent, reactivates latent HIV-1 infection without cellular activation or proliferation

  2026cites this paper
• Stochastic Modeling and Optimal Control of HIV-1 Infection Dynamics Under Combination Antiretroviral Therapy

  2026cites this paper
• CD169 expression of CD14+ monocyte as a biomarker in the early infection of HIV-1

  2026cites this paper
• Rapid clearance of inducible HIV-1 proviruses after initiation of antiretroviral therapy

  2025cites this paper
• Immune Alterations and Viral Reservoir Atlas in SIV-Infected Chinese Rhesus Macaques

  2025cites this paper
• The TLR7 agonist vesatolimod does not measurably induce SIV expression in macaques receiving combination antiretroviral therapy initiated during chronic infection

  2025cites this paper
• Inducible HIV-1 Reservoir Reduction Assay (HIVRRA), a Fast and Sensitive Assay to Test Cytotoxicity and Potency of Cure Strategies to Reduce the Replication-Competent HIV-1 Reservoir in Ex Vivo PBMCs

  2025cites this paper
• A Participant-Derived Xenograft Mouse Model to Decode Autologous Mechanisms of HIV Control and Evaluate Immunotherapies

  2025cites this paper
• Yoda1, a Piezo1 agonist, induced latent HIV reactivation associated with upregulation of CD3/TCR complex and HLA genes

  2025cites this paper
• Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection

  2025cites this paper
• Acute HIV Infection and ART Response: Insights into T Cell Subsets, Activation, Exhaustion, and Blood and GALT HIV Reservoir

  2025cites this paper
• Host-directed approaches in the pursuit of a cure for HIV.

  2025cites this paper
• Proviruses in CD4+ T cells reactive to autologous antigens contribute to nonsuppressible HIV-1 viremia.

  2025cites this paper
• Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaques

  2025cites this paper
• Targeted bacteriophage T4 nanoparticles reverse HIV-1 latency in human T cell line models

  2025cites this paper
• Impact of increased uptake of long-acting injectable antiretroviral therapy on HIV incidence and viral suppression in the United States under 2021 FDA guidelines

  2025cites this paper
• Distinguishable topological properties of functional genome networks in HIV-1 reservoirs

  2024cites this paper
• Balancing mitigation strategies for viral outbreaks.

  2024cites this paper
• Nonnegligible Contribution of Nonlymphoid Tissue to Viral Reservoir During the Short-Term Early cART in SIVmac239-Infected Chinese Rhesus Macaques

  2024cites this paper
• Viral and immune predictors of HIV posttreatment control

  2024cites this paper
• Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection

  2024cites this paper
• Immune checkpoint inhibition as a therapeutic strategy for HIV eradication: current insights and future directions

  2024cites this paper
• Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fcγ receptors during acute SHIVAD8-EO infection

  2024influential citation
• HIV Persistence, Latency, and Cure Approaches: Where Are We Now?

  2024cites this paper
• HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort Study

  2024cites this paper
• Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases

  2024cites this paper
• Production and Characterization of Novel Anti-HIV Fc-Fusion Proteins in Plant-Based Systems: Nicotiana benthamiana & tobacco BY-2 cell suspension.

  2024cites this paper
• Investigating the role of nucleoside reverse transcriptase inhibitors in modulating lipotoxicity: Effects on lipid dynamics stress pathways, and insulin resistance on the function of dopaminergic neurons.

  2024cites this paper
• Monocyte to macrophage differentiation and changes in cellular redox homeostasis promote cell type-specific HIV latency reactivation

  2024cites this paper
• HIV Reservoirs and Treatment Strategies toward Curing HIV Infection

  2024cites this paper
• Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1

  2024cites this paper
• Effective in vivo reactivation of HIV-1 latency reservoir via oral administration of EK-16A-SNEDDS.

  2024cites this paper
• Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques

  2024cites this paper
• No evidence for ongoing replication on ART in SIV-infected macaques

  2024cites this paper
• Suppression of viral rebound by a Rev-dependent lentiviral particle in SIV-infected rhesus macaques

  2024cites this paper
• The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy.

  2024cites this paper
• Humanized mice for studying HIV latency and potentially its eradication

  2024cites this paper
• The Many Faces of Immune Activation in HIV-1 Infection: A Multifactorial Interconnection

  2023cites this paper
• Targeting and eradicating latent CNS reservoirs of HIV-1: original strategies and new models.

  2023cites this paper
• Modeling the cytotoxicity of Romidepsin reveals the ineffectiveness of this drug in the “shock and kill” strategy

  2023cites this paper
• Virological and immunological correlates of HIV posttreatment control after temporal antiretroviral therapy during acute HIV infection

  2023cites this paper
• Current Advances in Humanized Mouse Models for Studying NK Cells and HIV Infection

  2023cites this paper
• To prescreen or not to prescreen for broadly neutralizing antibody sensitivity in HIV cure-related trials

  2023cites this paper
• Nanodepots Encapsulating a Latency Reversing Agent and Broadly Neutralizing Antibody Enhance Natural Killer Cell Cytotoxicity Against an in vitro Model of Latent HIV

  2023cites this paper
• Humanized Mice for Studies of HIV-1 Persistence and Elimination

  2023cites this paper
• Advances in Pediatric HIV-1 Cure Therapies and Reservoir Assays

  2022cites this paper
• Towards a new combination therapy with vectored immunoprophylaxis for HIV: Modeling "shock and kill" strategy.

  2022cites this paper
• A modular CRISPR screen identifies individual and combination pathways contributing to HIV-1 latency

  2022cites this paper
• High frequency of CD8 escape mutations in elite controllers as new obstacle for HIV cure

  2022cites this paper
• Potential multi-modal effects of provirus integration on HIV-1 persistence: lessons from other viruses.

  2022cites this paper
• cART Restores Transient Responsiveness to IFN Type 1 in HIV-Infected Humanized Mice

  2022cites this paper
• Changes to the Simian Immunodeficiency Virus (SIV) Reservoir and Enhanced SIV-Specific Responses in a Rhesus Macaque Model of Functional Cure after Serial Rounds of Romidepsin Administrations

  2022cites this paper
• A Dynamic Interplay of Circulating Extracellular Vesicles and Galectin-1 Reprograms Viral Latency during HIV-1 Infection

  2022cites this paper
• Macrophage Targeting for Therapy of HIV

  2022cites this paper
• TCR-mimic bispecific antibodies to target the HIV-1 reservoir

  2022cites this paper
• So Pathogenic or So What?—A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research

  2022cites this paper
• Engineered Zinc Finger Protein Targeting 2LTR Inhibits HIV Integration in Hematopoietic Stem and Progenitor Cell-Derived Macrophages: In Vitro Study

  2022cites this paper
• Nanomedicines encountering HIV dementia: A guiding star for neurotherapeutics

  2022cites this paper
• Extracellular Vesicles as a New Promising Therapy in HIV Infection

  2022cites this paper
• Antiretroviral drug exposure in lymph nodes is heterogeneous and drug dependent

  2022cites this paper
• Latency reversal plus natural killer cells diminish HIV reservoir in vivo

  2022cites this paper
• Isolation, Synthesis, and Structure-Activity Relationship Study on Daphnane and Tigliane Diterpenes as HIV Latency-Reversing Agents.

  2022cites this paper
• Cardiovascular Disease and Thrombosis in HIV Infection

  2022cites this paper
• IMMUNOMETABOLIC REPROGRAMMING DURING SUPPRESSIVE HIV-1 INFECTION

  2022cites this paper
• HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys

  2022cites this paper
• Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir

  2021cites this paper
• Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy.

  2021cites this paper
• A Note on the Vaccines for the Treatment of HIV

  2021influential citation
• Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies.

  2021cites this paper
• Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges

  2021cites this paper
• Naive infection predicts reservoir diversity and is a formidable hurdle to HIV eradication

  2021influential citation
• Targeted Bacteriophage T4 Nanoparticles Reverse HIV-1 Latency in CD4+ Human T Cells

  2021cites this paper
• Shocking HIV-1 with immunomodulatory latency reversing agents.

  2021cites this paper
• Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques

  2021cites this paper
• Measuring Proviral HIV-1 DNA: Hurdles and Improvements to an Assay Monitoring Integration Events Utilising Human Alu Repeat Sequences

  2021cites this paper
• Atlas of the HIV-1 Reservoir in Peripheral CD4 T Cells of Individuals on Successful Antiretroviral Therapy

  2021cites this paper
• Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, Reverse Transcriptase Simian-Human Immunodeficiency Virus RNA, and Collagen in the Mesenteric Lymph Nodes of Nonhuman Primates

  2021cites this paper
• Broadly neutralizing antibody–derived CAR T cells reduce viral reservoir in individuals infected with HIV-1

  2021cites this paper
• Cell-associated HIV RNA has a Circadian Cycle in Males Living with HIV on Antiretroviral Therapy.

  2021cites this paper
• Clonal Expansion of Infected CD4+ T Cells in People Living with HIV

  2021cites this paper
• Genome editing in large animal models.

  2021cites this paper
• Gut microbiome signatures linked to HIV-1 reservoir size and viremia control

  2021cites this paper
• Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals

  2021cites this paper
• CpG Methylation Profiles of HIV-1 Proviral DNA in Individuals on ART

  2021cites this paper
• Broadly neutralizing antibody-derived CAR-T cells reduce viral reservoir in HIV-1-infected individuals.

  2021cites this paper
• Human Immunodeficiency Virus Type-1 (HIV-1) Transcriptional Regulation, Latency and Therapy in the Central Nervous System

  2021cites this paper
• TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure

  2021cites this paper
• Therapeutic Vaccines for the Treatment of HIV.

  2020cites this paper
• Measuring the Success of HIV-1 Cure Strategies

  2020cites this paper
• Identification of a lymphocyte minor histocompatibility antigen in Mauritian cynomolgus macaques

  2020cites this paper
• Drug Delivery System Targeting CD4+ T Cells for HIV-1 Latency Reactivation Towards the Viral Eradication.

  2020cites this paper
• RETRACTED: No glove, no love: General intelligence predicts increased likelihood of condom use in response to HIV threat

  2020cites this paper
• Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches

  2020cites this paper
• Pre-existing resistant proviruses can compromise maintenance of remission by VRC01 in chronic HIV-1 infection

  2020cites this paper
• DNA dependent protein kinase (DNA-PK) enhances HIV transcription by promoting RNA polymerase II activity and recruitment of transcription machinery at HIV LTR

  2020cites this paper
• Anti-HIV-1 Antibodies: An Update

  2020cites this paper
• Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques

  2020cites this paper